266 related articles for article (PubMed ID: 27859023)
1. Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis.
Dujic T; Zhou K; Yee SW; van Leeuwen N; de Keyser CE; Javorský M; Goswami S; Zaharenko L; Hougaard Christensen MM; Out M; Tavendale R; Kubo M; Hedderson MM; van der Heijden AA; Klimčáková L; Pirags V; Kooy A; Brøsen K; Klovins J; Semiz S; Tkáč I; Stricker BH; Palmer C; 't Hart LM; Giacomini KM; Pearson ER
Clin Pharmacol Ther; 2017 Jun; 101(6):763-772. PubMed ID: 27859023
[TBL] [Abstract][Full Text] [Related]
2. Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes.
Phani NM; Vohra M; Kakar A; Adhikari P; Nagri SK; D'Souza SC; Umakanth S; Satyamoorthy K; Rai PS
Pharmacogenomics; 2018 Jul; 19(11):905-911. PubMed ID: 29914345
[TBL] [Abstract][Full Text] [Related]
3. Altered Glycemic Control Associated With Polymorphisms in the SLC22A1 (OCT1) Gene in a Mexican Population With Type 2 Diabetes Mellitus Treated With Metformin: A Cohort Study.
Reséndiz-Abarca CA; Flores-Alfaro E; Suárez-Sánchez F; Cruz M; Valladares-Salgado A; Del Carmen Alarcón-Romero L; Vázquez-Moreno MA; Wacher-Rodarte NA; Gómez-Zamudio JH
J Clin Pharmacol; 2019 Oct; 59(10):1384-1390. PubMed ID: 31012983
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic Evaluation of Metformin and Sulphonylurea Response in Mexican Mestizos with Type 2 Diabetes.
Marta M; Sánchez-Pozos K; Jaimes-Santoyo J; Monroy-Escutia J; Rivera-Santiago C; de Los Ángeles Granados-Silvestre M; Ortiz-López MG
Curr Drug Metab; 2020; 21(4):291-300. PubMed ID: 32407269
[TBL] [Abstract][Full Text] [Related]
5. Lack of effect of the SLC47A1 and SLC47A2 gene polymorphisms on the glycemic response to metformin in type 2 diabetes mellitus patients.
Raj GM; Mathaiyan J; Wyawahare M; Priyadarshini R
Drug Metab Pers Ther; 2018 Dec; 33(4):175-185. PubMed ID: 30433870
[TBL] [Abstract][Full Text] [Related]
6. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients.
Tarasova L; Kalnina I; Geldnere K; Bumbure A; Ritenberga R; Nikitina-Zake L; Fridmanis D; Vaivade I; Pirags V; Klovins J
Pharmacogenet Genomics; 2012 Sep; 22(9):659-66. PubMed ID: 22735389
[TBL] [Abstract][Full Text] [Related]
7. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study.
Zhou K; Donnelly LA; Kimber CH; Donnan PT; Doney AS; Leese G; Hattersley AT; McCarthy MI; Morris AD; Palmer CN; Pearson ER
Diabetes; 2009 Jun; 58(6):1434-9. PubMed ID: 19336679
[TBL] [Abstract][Full Text] [Related]
8. Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients.
Hou W; Zhang D; Lu W; Zheng T; Wan L; Li Q; Bao Y; Liu F; Jia W
Mol Diagn Ther; 2015 Feb; 19(1):25-33. PubMed ID: 25573751
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes: A systematic review.
Mofo Mato EP; Guewo-Fokeng M; Essop MF; Owira PMO
Medicine (Baltimore); 2018 Jul; 97(27):e11349. PubMed ID: 29979413
[TBL] [Abstract][Full Text] [Related]
10. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin.
Shikata E; Yamamoto R; Takane H; Shigemasa C; Ikeda T; Otsubo K; Ieiri I
J Hum Genet; 2007; 52(2):117-122. PubMed ID: 17111267
[TBL] [Abstract][Full Text] [Related]
11. Single nucleotide polymorphisms in the intergenic region between metformin transporter OCT2 and OCT3 coding genes are associated with short-term response to metformin monotherapy in type 2 diabetes mellitus patients.
Zaharenko L; Kalnina I; Geldnere K; Konrade I; Grinberga S; Židzik J; Javorský M; Lejnieks A; Nikitina-Zake L; Fridmanis D; Peculis R; Radovica-Spalvina I; Hartmane D; Pugovics O; Tkáč I; Klimčáková L; Pīrāgs V; Klovins J
Eur J Endocrinol; 2016 Dec; 175(6):531-540. PubMed ID: 27609360
[TBL] [Abstract][Full Text] [Related]
12. Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects.
Yoon H; Cho HY; Yoo HD; Kim SM; Lee YB
AAPS J; 2013 Apr; 15(2):571-80. PubMed ID: 23417334
[TBL] [Abstract][Full Text] [Related]
13. Association between organic cation transporter genetic polymorphisms and metformin response and intolerance in T2DM individuals: a systematic review and meta-analysis.
Peng A; Gong C; Xu Y; Liang X; Chen X; Hong W; Yan J
Front Public Health; 2023; 11():1183879. PubMed ID: 37546319
[TBL] [Abstract][Full Text] [Related]
14. The variant organic cation transporter 2 (OCT2)-T201M contribute to changes in insulin resistance in patients with type 2 diabetes treated with metformin.
Kashi Z; Masoumi P; Mahrooz A; Hashemi-Soteh MB; Bahar A; Alizadeh A
Diabetes Res Clin Pract; 2015 Apr; 108(1):78-83. PubMed ID: 25662675
[TBL] [Abstract][Full Text] [Related]
15. A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin.
Goswami S; Yee SW; Xu F; Sridhar SB; Mosley JD; Takahashi A; Kubo M; Maeda S; Davis RL; Roden DM; Hedderson MM; Giacomini KM; Savic RM
Clin Pharmacol Ther; 2016 Nov; 100(5):537-547. PubMed ID: 27415606
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms of organic cation transporters 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes mellitus: a systematic review protocol.
Mato EPM; Guewo-Fokeng M; Faadiel Essop M; Owira PMO
Syst Rev; 2018 Jul; 7(1):105. PubMed ID: 30041690
[TBL] [Abstract][Full Text] [Related]
17. The influence of SLC22A3 rs543159 and rs1317652 genetic variants on metformin therapeutic efficacy in newly diagnosed patients with type 2 diabetes mellitus: 25 weeks follow-up study.
Taheri R; Kazerouni F; Mirfakhraei R; Kalbasi S; Shahrokhi SZ; Rahimipour A
Gene; 2022 May; 823():146382. PubMed ID: 35240257
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic variation and metformin response.
Chen S; Zhou J; Xi M; Jia Y; Wong Y; Zhao J; Ding L; Zhang J; Wen A
Curr Drug Metab; 2013 Dec; 14(10):1070-82. PubMed ID: 24329113
[TBL] [Abstract][Full Text] [Related]
19. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.
Tzvetkov MV; Vormfelde SV; Balen D; Meineke I; Schmidt T; Sehrt D; Sabolić I; Koepsell H; Brockmöller J
Clin Pharmacol Ther; 2009 Sep; 86(3):299-306. PubMed ID: 19536068
[TBL] [Abstract][Full Text] [Related]
20. Identification of clinical and pharmacogenetic factors influencing metformin response in Type 2 diabetes mellitus.
Pérez-Gómez N; Fernández-Ortega MD; Elizari-Roncal M; Santos-Mazo E; la Maza-Pereg L; Calvo S; Alcaraz R; Sanz-Solas A; Vinuesa R; Saiz-Rodríguez M
Pharmacogenomics; 2023 Aug; 24(12):651-663. PubMed ID: 37610884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
